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Serum protease inhibitor activity was assessed from the ability of the serum to inhibit casein hydrolysis by ct-chymotrypsin (EC 3.4.4.5). Unmodified AutoAnalyzer equipment was used in conjunction with a fluorimetric method for dialyzable tyrosyl peptides. Serum, diluted with tris(hydroxymethyl) aminomethane buffer, was added to a chymotrypsin solution to inhibit its activity. For 72 sera, the automated method was compared with a manual determination of trypsin inhibitor capacity. Results by the two methods correlate well, supporting previous evidence that trypsin-and chymotrypsin-inhibitor capacities of serum are related. The present automated method has several advantages that make it useful for clinical studies. (80 g/ml), is mixed with an equal volume of human serum diluted with the same buffer to allow a protease-inhibitor complex to form. All other reagents are as previously described
Materials and Methods
Principle
(13).
Dilute specimens 10-fold with the Tris buffer, on the day of determination: to 5 ml of chymotrypsin solution (80 xg/ml) add 4 ml of Tris buffer and 1 ml
and 0.5 ml of 10-fold diluted serum). Compare all specimens with the reference control standard, which is mixed with an equal quantity of Tris buffer without serum. Use sera of known inhibitor concentration to check reproducibility.
Apparatus Figure 1 shows the flow diagram of the AutoAnalyzer equipment.
A (b) the tyrosine dialyzed from the reaction mixture is only about 15% of the total quantity of tyrosine generated in this reaction, but it is a constant proportion of the total, and is linear with respect to concentration of enzyme added to the substrate (see Table 1 ). (1, 14) . The present automated method permits both increased and decreased activities of protease inhibitors to be accurately measured in serum. Several diseases in which a globulin-protease interaction is important are under intensive investigation (1) (2) (3) (4) 15) . Because some of these circulating inhibitors may be nonfunctional as a result of being bound to the enzymes, immunochemical quantitations are also needed for a clear determination of these inter-relationships; none of these techniques can, by itself, suffice for all clinical applications.
